Clinical features and genetic results of 6 cases with pseudohypoaldosteronism type 1 and literature review
10.3760/cma.j.cn101070-20200528-00900
- VernacularTitle:假性醛固酮减少症1型6例患儿的临床特征及基因结果并文献复习
- Author:
Yan GONG
1
;
Sheng GUO
;
Pin LI
Author Information
1. 上海市儿童医院，上海交通大学附属儿童医院内分泌遗传代谢科，上海 200062
- Keywords:
Hyponatremia;
Hyperkalemia;
Pseudohypoaldosteronism type 1;
Urinary tract anomalies;
SCNN1A gene
- From:
Chinese Journal of Applied Clinical Pediatrics
2021;36(21):1648-1650
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To summarize clinical features, diagnosis, treatment, and follow-up of children with pseudohypoaldosteronism type 1 (PHA1) and review relevant literatures to improve the understanding of the disease and reduce misdiagnosis.Methods:Six children with the main performance of salt losing treated in the Shanghai Children′s Hospital from January 2015 to December 2018, who were diagnosed as PHA1 after relevant auxiliary examinations and genetic tests.They were classified and analyzed for their treatment courses and follow-up prognosis.Results:Six children with PHA1 had varying degrees of salt losing, dehydration and infection.After the examination, 3 cases with urinary system malformations were diagnosed as secondary PHA1.Genetic testing of 2 cases revealed 2 hete-rozygous mutations c. 1439+ 1G>C and c. 875+ 1G>A in the intron region of the SCNN1A gene, and they were diagnosed as multiple target organ defect/systemic PHA1 according to American College of Medical Genetics and Genomics(ACMG) guidelines.The other case failed to be examined by genetic testing due to the refusal of parents, and was finally diagnosed as renal PHA1 according to clinical diagnosis and treatment.Conclusions:PHA1 is a rare cause of infant salt-losing syndrome, renal and secondary PHA1 children can recover quickly after sodium supplementation and the secondary factors are removed; while multiple target organ defect/systemic PHA1 has severe clinical manifestations, electrolyte imbalance is not easy to correct, and fatal arrhythmia is prone to occur, the mortality rate is high.It is easy to be misdiagnosed in clinical practice.Auxiliary examination and genetic testing can help to diagnose and classify PHA1, as well as individualized treatment.
